AMENDMENTS TO THE CLAIMS:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) Pharmaceutical composition for use in the treatment of pain and inflammatory diseases, wherein it comprises a combination of tenatoprazole and one or more anti-inflammatory agents, wherein the anti-inflammatory agent is a nonsteroidal anti-inflammatory agent selected from the group consisting of aspirin, diclofenac, etodolac, indometacin, naproxen, ibuprofen and piroxicam, or a cyclooxygenase-2 inhibitor selected from the group consisting of rofecoxib and celecoxib .

2. – 5.   (Canceled)

6. (Currently Amended) Composition according to claim 1, wherein the weight ratio tenatoprazole : anti-inflammatory agent is ~~comprised~~ between 1:2 and 1:40.

7. (Previously Presented) Composition according to claim 1, wherein the composition comprises unitary doses each containing from 10 to 60 mg of tenatoprazole and from 10 to 500 mg of anti-inflammatory agent.

8. (Original) Composition according to claim 1, wherein tenatoprazole is in the form of a potassium, magnesium, sodium or calcium salt.

9. (Previously Presented) Composition according to claim 1, wherein the composition is in a standard form adapted for administration via the oral or the parenteral route.

10. -14. (Canceled)

15. (Currently Amended) Composition according to claim 1 2, wherein the composition comprises unitary doses each containing from 10 to 60 mg of tenatoprazole and from 10 to 500 mg of anti-inflammatory agent.

16. - 20. (Canceled)

21. (Previously Presented) A medicament for the treatment of pain and inflammatory diseases composed of tenatoprazole and one or more anti-inflammatory agents, wherein the anti-inflammatory agent is a nonsteroidal anti-inflammatory agent selected from the group consisting of aspirin, diclofenac, etodolac, indometacin, naproxen, ibuprofen and piroxicam, or a cyclooxygenase-2 inhibitor selected from the group consisting of rofecoxib and celecoxib.